A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 957
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : hERG
Long Form : human ether-a-go-go-related gene
No. Year Title Co-occurring Abbreviation
2022 The Linkage Phase of the Polymorphism KCNH2-K897T Influences the Electrophysiological Phenotype in hiPSC Models of LQT2. hiPSC-CMs, hiPSCs, LQT2, SNP
2021 2-((2-(4-Iodo-2,5-dimethoxyphenyl)ethylamino)methyl)phenol (25I-NBOH) and 2-(((2-(4-chloro-2,5-dimethoxyphenyl)ethyl)amino)methyl)phenol (25C-NBOH) induce adverse effects on the cardiovascular system. ECG, LVDP, NPSs, PAK1
2021 A Phase 1 Study to Investigate the Effects of Cortexolone 17alpha-Propionate, Also Known as Clascoterone, on the QT Interval Using the Meal Effect to Demonstrate ECG Assay Sensitivity. ---
2021 Absence of effect of steady state bempedoic acid on cardiac repolarization: Results of a thorough QT/QTc study in healthy volunteers. CI, QTcF
2021 Anti-Ro/SSA Antibodies and the Autoimmune Long-QT Syndrome. AD, LQTS, TdP
2021 Association between the serum concentrations and mutational status of IL-8, IL-27 and VEGF and the expression levels of the hERG potassium channel gene in patients with colorectal cancer. CRC
2021 Berberine on the Prevention and Management of Cardiometabolic Disease: Clinical Applications and Mechanisms of Action. AMPK, mTOR, PCSK9
2021 Cardiotoxicity assessment using 3D vascularized cardiac tissue consisting of human iPSC-derived cardiomyocytes and fibroblasts. ADD, hiPSC-CMs, MCS
2021 Computational and experimental studies on the inhibitory mechanism of hydroxychloroquine on hERG. FQs, HCQ, SAES-CoV-2
10  2021 COVID-19 Drugs Chloroquine and Hydroxychloroquine, but Not Azithromycin and Remdesivir, Block hERG Potassium Channels. LQTS
11  2021 Discovery of 6-[(3S,4S)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one (IACS-15414), a Potent and Orally Bioavailable SHP2 Inhibitor. KRAS, MAPK, NF-1, PK, RTK, SH2
12  2021 Discovery of a new class of multi-target heterocycle piperidine derivatives as potential antipsychotics with pro-cognitive effect. DA
13  2021 Discovery of a novel series of GPR119 agonists: Design, synthesis, and biological evaluation of N-(Piperidin-4-yl)-N-(trifluoromethyl)pyrimidin-4-amine derivatives. GPR119
14  2021 Discovery of a novel series of indolinylpyrimidine-based GPR119 agonists: Elimination of ether-a-go-go-related gene liability using a hydrogen bond acceptor-focused approach. HBA
15  2021 Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell Lymphomas. EZH2, SAR
16  2021 Discovery of Novel Thiophene-arylamide Derivatives as DprE1 Inhibitors with Potent Antimycobacterial Activities. MIC
17  2021 Disruption of protein quality control of the human ether-à-go-go related gene K+ channel results in profound long QT syndrome. hiPSC-CMs, LQTS, RNF207
18  2021 Dual Mechanisms of Cardiac Action Potential Prolongation by 4-Oxo-Nonenal Increasing the Risk of Arrhythmia; Late Na+ Current Induction and hERG K+ Channel Inhibition. 4-HNE, 4-ONE, APD, INaL
19  2021 Flavonoids and hERG channels: Friends or foes? ---
20  2021 Ginsenoside Rg3 Alleviates Antithyroid Cancer Drug Vandetanib-Induced QT Interval Prolongation. ECG, hiPSC-CMs, MAP
21  2021 hERG-deficient human embryonic stem cell-derived cardiomyocytes for modelling QT prolongation. CM, hESC, LQT2, MEA
22  2021 Induced Pluripotent Stem Cell-Derived Cardiomyocytes with SCN5A R1623Q Mutation Associated with Severe Long QT Syndrome in Fetuses and Neonates Recapitulates Pathophysiological Phenotypes. CM, EAD, iPSC, LQT3
23  2021 Investigation of PAS and CNBH domain interactions in hERG channels and effects of long-QT syndrome-causing mutations with surface plasmon resonance. CNBH, LQTS, PAS, SPR
24  2021 L51P, a novel mutation in the PAS domain of hERG channel, confers long QT syndrome by impairing channel activation. LQTS, MD, PAS, PME
25  2021 Mechanisms of gefitinib-induced QT prolongation. APD, NSCLC
26  2021 Molecular dynamics of hERG channel: insights into understanding the binding of small molecules for detuning cardiotoxicity. NCEs
27  2021 Novel bicyclic pyrazoles as potent ALK2 (R206H) inhibitors for the treatment of fibrodysplasia ossificans progressiva. ALK2, BMP
28  2021 Parallel Recordings of Transmembrane hERG Channel Currents Based on Solvent-Free Lipid Bilayer Microarray. BLMs, Si
29  2021 Pharmacological corrections of the mutant hERG channels by posaconazole. HEK, WT
30  2021 Preclinical Evaluation of the Effects of Trazpiroben (TAK-906), a Novel, Potent Dopamine D2/D3 Receptor Antagonist for the Management of Gastroparesis. 5-HT, AEs
31  2021 Proarrhythmic effects induced by benzethonium chloride and domiphen bromide in vitro and in vivo. BZT, DMP, hiPSC-CMs
32  2021 Refinement of a cryo-EM structure of hERG: Bridging structure and function. MDFF, VSD
33  2021 Role and mechanism of chaperones calreticulin and ERP57 in restoring trafficking to mutant HERG‑A561V protein. CNX, CRT, ERP57, WT
34  2021 Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK-906), a Novel Selective D2 /D3 Receptor Antagonist: A Phase 1 Randomized, Placebo-Controlled Single- and Multiple-Dose Escalation Study in Healthy Participants. CNS
35  2021 Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Mycobacterium tuberculosis Growth. TB
36  2021 Structure-Based Prediction of hERG-Related Cardiotoxicity: A Benchmark Study. IFs, SVM
37  2021 The Effect of a Synthetic Estrogen, Ethinylestradiol, on the hERG Block by E-4031. ---
38  2021 TSSF-hERG: A machine-learning-based hERG potassium channel-specific scoring function for chemical cardiotoxicity prediction. RMSE, Rs, SVR
39  2020 AKAP5 anchors PKA to enhance regulation of the HERG channel. AKAPs, beta-AR, LQTS, PKA
40  2020 Assessment of spatial heterogeneity of ventricular repolarization after multi-channel blocker drugs in healthy subjects. SHVR
41  2020 Benzoxazepine-Derived Selective, Orally Bioavailable Inhibitor of Human Acidic Mammalian Chitinase. hAMCase
42  2020 Critical Assessment of Artificial Intelligence Methods for Prediction of hERG Channel Inhibition in the "Big Data" Era. AI, DNNs, RNNs
43  2020 Current development of integrated web servers for preclinical safety and pharmacokinetics assessments in drug development. ---
44  2020 DeepHIT: a deep learning framework for prediction of hERG-induced cardiotoxicity. NPV, UT
45  2020 Discovery of a Novel Class of State-Dependent NaV1.7 Inhibitors for the Treatment of Neuropathic Pain. CNS, NaV
46  2020 Discovery of FNDR-20123, a histone deacetylase inhibitor for the treatment of Plasmodium falciparum malaria. HDAC, MDR
47  2020 Discovery of novel histone lysine methyltransferase G9a/GLP (EHMT2/1) inhibitors: Design, synthesis, and structure-activity relationships of 2,4-diamino-6-methylpyrimidines. ---
48  2020 Fentanyl-Induced Block of hERG Channels Is Exacerbated by Hypoxia, Hypokalemia, Alkalosis, and the Presence of hERG1b. ---
49  2020 Formulation of Liver-Specific PLGA-DY-635 Nanoparticles Loaded with the Protein Kinase C Inhibitor Bisindolylmaleimide I. BIM I, PLGA
50  2020 G604S-HERG mutation in LQT2 leads to autophagy via the UPR-related pathway. ER, ERS, LQTS, UPR
51  2020 HERG channel and cancer: A mechanistic review of carcinogenic processes and therapeutic potential. ---
52  2020 hERG toxicity assessment: Useful guidelines for drug design. EMA, FDA
53  2020 hERG-Att: Self-attention-based deep neural network for predicting hERG blockers. ---
54  2020 In vitro and in vivo cardiac toxicity of flavored electronic nicotine delivery systems. ENDS
55  2020 In-vitro safety and off-target profile of the anti-parasitic arylmethylaminosteroid 1o. HDAC, PDE, sc1o, TEER
56  2020 Inhibition of Human Ether-A-Go-Go-Related Gene (hERG) Potassium Current by the Novel Sotalol Analogue, Soestalol. ---
57  2020 Inhibitory effects of four active components in saffron on human ether-a-go-go-related gene (hERG) K+ currents. ---
58  2020 Introduction to in silico model for proarrhythmic risk assessment under the CiPA initiative. CiPA, ICH, TdP
59  2020 Lerisetron Analogues with Antimalarial Properties: Synthesis, Structure-Activity Relationship Studies, and Biological Assessment. ---
60  2020 Letrozole targets the human ether-a-go-go-related gene potassium current in glioblastoma. GBM
61  2020 Neurological Disorders and Risk of Arrhythmia. ANS, HPA, PTSD
62  2020 Novel Indirect AMP-Activated Protein Kinase Activators: Identification of a Second-Generation Clinical Candidate with Improved Physicochemical Properties and Reduced hERG Inhibitory Activity. AMPK
63  2020 Prediction of hERG potassium channel blockage using ensemble learning methods and molecular fingerprints. AUC
64  2020 Serine mutation of a conserved threonine in the hERG K+ channel S6-pore region leads to loss-of-function through trafficking impairment. WT
65  2020 Structure-Activity Relationship Exploration of NNIBP Tolerant Region I Leads to Potent HIV-1 NNRTIs. ETR, HIV-1, NNRTI
66  2020 Synthesis and pharmacological evaluation of piperidine (piperazine)-amide substituted derivatives as multi-target antipsychotics. ---
67  2020 Synthesis, crystal structures, antiproliferative activities and reverse docking studies of eight novel Schiff bases derived from benzil. BDH, BDHAI, BMH
68  2020 The hERG channel activator, RPR260243, enhances protective IKr current early in the refractory period reducing arrhythmogenicity in zebrafish hearts. APD
69  2020 The Study on the hERG Blocker Prediction Using Chemical Fingerprint Analysis. DL, ML, QSAR
70  2020 Torsadogenic potential of a novel remyelinating drug clemastine for multiple sclerosis assessed in the rabbit proarrhythmia model. MAP
71  2020 When Does the IC50 Accurately Assess the Blocking Potency of a Drug? ---
72  2019 2-(2,5-Dimethoxy-4-methylphenyl)-N-(2-methoxybenzyl)ethanamine (25D-NBOMe) and N-(2-methoxybenzyl)-2,5-dimethoxy-4-chlorophenethylamine (25C-NBOMe) induce adverse cardiac effects in vitro and in vivo. ECG, PAK1
73  2019 Aggregation-Induced Emission: Lighting Up hERG Potassium Channel. ---
74  2019 Astemizole-based turn-on fluorescent probes for imaging hERG potassium channel. ---
75  2019 Blockade of the Human Ether A-Go-Go-Related Gene (hERG) Potassium Channel by Fentanyl. AP
76  2019 Calculation of absolute binding free energies between the hERG channel and structurally diverse drugs. ---
77  2019 Cardiotoxic effects of [3-[2-(diethylamino)ethyl]-1H-indol-4-yl] acetate and 3-[2-[ethyl(methyl)amino]ethyl]-1H-indol-4-ol. ECG, MTT, NPSs, PAK1
78  2019 Classification of drug-induced hERG potassium-channel block from electrocardiographic T-wave features using artificial neural networks. ANN, HB, LB, OANN, TdP, VM
79  2019 Clinical Trial in a Dish: Personalized Stem Cell-Derived Cardiomyocyte Assay Compared With Clinical Trial Results for Two QT-Prolonging Drugs. APD, iPSC-CMs, iPSCs
80  2019 Computational determination of hERG-related cardiotoxicity of drug candidates. AUC, LQTS, MCC
81  2019 Deep Learning-Based Prediction of Drug-Induced Cardiotoxicity. AUC, DNN, FDA, GCNN, NB, RF, SVM
82  2019 Design, synthesis, and biological evaluation of novel tetrahydroprotoberberine derivatives (THPBs) as proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators for the treatment of hyperlipidemia. DiI-LDL, LDL-C, LDLR, PCSK9, TC, THPBs
83  2019 Differential Regulation of Human Ether-a-Go-Go-Related Gene (hERG) Current and Expression by Activation of Protein Kinase C. HEK293, PKC, PMA
84  2019 Electrophysiological characterization of a small molecule activator on human ether-a-go-go-related gene (hERG) potassium channel. ---
85  2019 Facilitation of I Kr current by some hERG channel blockers suppresses early afterdepolarizations. ---
86  2019 GZ-11608, a Vesicular Monoamine Transporter-2 Inhibitor, Decreases the Neurochemical and Behavioral Effects of Methamphetamine. VMAT2
87  2019 Human ether‑a‑go‑go‑related gene mutation L539fs/47‑hERG leads to cell apoptosis through the endoplasmic reticulum stress pathway. ER, ERS, LQTS
88  2019 Hypoxia induced hERG trafficking defect linked to cell cycle arrest in SH-SY5Y cells. ER, ROS
89  2019 Importance of the Choice of a Recombinant System to Produce Large Amounts of Functional Membrane Protein hERG. ---
90  2019 In silico Assessment of Pharmacotherapy for Human Atrial Patho-Electrophysiology Associated With hERG-Linked Short QT Syndrome. AF, AP, APD, DF, ERP, SQT1, WT
91  2019 Molecular Docking Guided Grid-Independent Descriptor Analysis to Probe the Impact of Water Molecules on Conformational Changes of hERG Inhibitors in Drug Trapping Phenomenon. aLQTS, MIFs, PLIF
92  2019 Prediction of hERG K+ channel blockage using deep neural networks. ---
93  2019 Probucol-induced hERG Channel Reduction can be Rescued by Matrine and Oxymatrine in vitro. APD, LQTS, Sp1
94  2019 Rapid Characterization of hERG Channel Kinetics II: Temperature Dependence. ---
95  2019 Revealing Molecular Determinants of hERG Blocker and Activator Binding. ---
96  2019 Semisynthetic aurones inhibit tubulin polymerization at the colchicine-binding site and repress PC-3 tumor xenografts in nude mice and myc-induced T-ALL in zebrafish. SAR, T-ALL
97  2019 Stop codons and the +4 nucleotide may influence the efficiency of G418 in rescuing nonsense mutations of the HERG gene. ---
98  2019 Superparamagnetic iron oxide nanoparticles (SPIONs) modulate hERG ion channel activity. APPA, MRI, NPs, SPIONs
99  2019 The influence of hERG1a and hERG1b isoforms on drug safety screening in iPSC-CMs. CiPA, ECG, iPSC-CMs, TdP
100  2019 Transmural and rate-dependent profiling of drug-induced arrhythmogenic risks through in silico simulations of multichannel pharmacology. AP, EAD, ENDO, EPI